<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Autoimmune conditions are associated with an elevated risk of lymphoproliferative <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, but few studies have investigated the risk of <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>From the US Surveillance Epidemiology and End Results (SEER)-Medicare database, 13 486 myeloid <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> patients (aged 67+ years) and 160 086 population-based controls were selected </plain></SENT>
<SENT sid="2" pm="."><plain>Logistic regression models adjusted for gender, age, race, calendar year and number of physician claims were used to estimate odds ratios (ORs) for <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> in relation to autoimmune conditions </plain></SENT>
<SENT sid="3" pm="."><plain>Multiple comparisons were controlled for using the Bonferroni correction (P&lt;0.0005) </plain></SENT>
<SENT sid="4" pm="."><plain>Autoimmune conditions, overall, were associated with an increased risk of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) (OR 1.29) and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, OR 1.50) </plain></SENT>
<SENT sid="5" pm="."><plain>Specifically, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was associated with <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> (OR 1.28), <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (OR 1.92), <z:e sem="disease" ids="C0032533" disease_type="Disease or Syndrome" abbrv="pmr">polymyalgia rheumatica</z:e> (OR 1.73), <z:hpo ids='HP_0001890'>autoimmune haemolytic anaemia</z:hpo> (OR 3.74), systemic <z:hpo ids='HP_0002633'>vasculitis</z:hpo> (OR 6.23), <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> (OR 1.72) and pernicious <z:hpo ids='HP_0001903'>anaemia</z:hpo> (OR 1.57) </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndrome</z:hpo> was associated with <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> (OR1.52) and pernicious <z:hpo ids='HP_0001903'>anaemia</z:hpo> (OR 2.38) </plain></SENT>
<SENT sid="7" pm="."><plain>Overall, autoimmune conditions were not associated with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (OR 1.09) or <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (OR 1.15) </plain></SENT>
<SENT sid="8" pm="."><plain>Medications used to treat autoimmune conditions, shared genetic predisposition and/or direct infiltration of bone marrow by autoimmune conditions, could explain these excess risks of <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> </plain></SENT>
</text></document>